Compare Stocks: DARE, INCR, CLNN, and RYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$4.15 +7.5%	$4.72	$3.25 ▼ $13.50	$49.60M	0.95	124,312 shs	138,750 shs
DARE Dare Bioscience	$0.75 +3.1%	$1.12	$0.69 ▼ $3.78	$14.27M	1.01	355,949 shs	153,216 shs
INCR InterCure	$5.31	$4.99	$3.40 ▼ $8.45	$58.07M	1.42	44,512 shs	1,229 shs
RYM RYTHM	$22.49 +7.7%	$21.96	$14.00 ▼ $53.65	$45.49M	9.44	14,560 shs	16,033 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	+7.51%	+13.70%	+1.47%	-30.95%	-32.74%
DARE Dare Bioscience	+3.07%	+6.06%	-2.66%	-65.54%	-63.52%
INCR InterCure	0.00%	+1.34%	+11.44%	+14.35%	-30.13%
RYM RYTHM	+7.69%	-2.91%	+11.44%	-19.64%	+2,248,599,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$4.15 +7.5%	$4.72	$3.25 ▼ $13.50	$49.60M	0.95	124,312 shs	138,750 shs
DARE Dare Bioscience	$0.75 +3.1%	$1.12	$0.69 ▼ $3.78	$14.27M	1.01	355,949 shs	153,216 shs
INCR InterCure	$5.31	$4.99	$3.40 ▼ $8.45	$58.07M	1.42	44,512 shs	1,229 shs
RYM RYTHM	$22.49 +7.7%	$21.96	$14.00 ▼ $53.65	$45.49M	9.44	14,560 shs	16,033 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	+7.51%	+13.70%	+1.47%	-30.95%	-32.74%
DARE Dare Bioscience	+3.07%	+6.06%	-2.66%	-65.54%	-63.52%
INCR InterCure	0.00%	+1.34%	+11.44%	+14.35%	-30.13%
RYM RYTHM	+7.69%	-2.91%	+11.44%	-19.64%	+2,248,599,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	2.71	Moderate Buy	$34.00	719.28% Upside
DARE Dare Bioscience	2.33	Hold	$6.50	769.22% Upside
INCR InterCure	1.00	Sell	N/A	N/A
RYM RYTHM	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest DARE, INCR, CLNN, and RYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	DARE Dare Bioscience	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1.00
9/10/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	RYM RYTHM	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/30/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$197K	270.68	N/A	N/A	($1.62) per share	-2.56
DARE Dare Bioscience	$1.03M	14.28	N/A	N/A	$0.20 per share	3.74
INCR InterCure	$78.47M	0.74	N/A	N/A	$10.53 per share	0.50
RYM RYTHM	$17.28M	2.84	N/A	N/A	$6.06 per share	3.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$26.17M	-$3.50	N/A	N/A	N/A	-20,063.96%	N/A	-137.04%	11/12/2026 (Estimated)
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
INCR InterCure	-$10.37M	$0.15	35.40	N/A	N/A	N/A	N/A	N/A	N/A
RYM RYTHM	-$33.26M	-$10.53	N/A	N/A	N/A	-6.20%	-12.57%	-2.60%	N/A

Latest DARE, INCR, CLNN, and RYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CLNN Clene	-$0.3680	-$1.08	-$0.7120	-$1.08	$0.06 million	$0.09 million
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million
8/4/2026	Q2 2026	RYM RYTHM	N/A	$0.09	N/A	$0.09	N/A	$23.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
RYM RYTHM	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	3.07	3.07
DARE Dare Bioscience	N/A	0.99	0.99
INCR InterCure	0.20	1.48	0.97
RYM RYTHM	N/A	0.59	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
DARE Dare Bioscience	6.70%
INCR InterCure	8.34%
RYM RYTHM	5.98%

Insider Ownership

Company	Insider Ownership
CLNN Clene	28.30%
DARE Dare Bioscience	4.10%
INCR InterCure	0.24%
RYM RYTHM	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	79	12.85 million	9.21 million	No Data
DARE Dare Bioscience	30	19.67 million	18.86 million	Not Optionable
INCR InterCure	285	10.94 million	10.91 million	Optionable
RYM RYTHM	141	2.18 million	2.10 million	N/A

DARE, INCR, CLNN, and RYM Headlines

Recent News About These Companies

RYTHM (NASDAQ:RYM) Shares Up 2% - What's Next?

August 26, 2026 | marketbeat.com

RYTHM Introduces Lifted Lemon, a New THC Twist on Iced Tea and Lemonade

August 20, 2026 | globenewswire.com

RYTHM Inc

August 19, 2026 | markets.ft.com

RYTHM Shareholders Approve Dilutive Equity Issuance Changes

August 11, 2026 | tipranks.com

RYTHM Swings to Earnings in Q2 on THC Beverage Growth

August 7, 2026 | zacks.com

RYTHM, Inc. Reports Record Second-Quarter 2026 Revenue Growth and Strong THC Beverage Momentum

August 4, 2026 | quiverquant.comQ

RYTHM, Inc. Reports Second Quarter 2026 Results

August 4, 2026 | globenewswire.com

RYTHM (NASDAQ:RYM) Trading Up 14% – Time to Buy?

August 4, 2026 | defenseworld.netD

RYTHM, Inc. (RYM) Stock Major Holders - Yahoo Finance

July 27, 2026 | ca.finance.yahoo.com

Señorita Brings THC Beverages to Lollapalooza for the First Time

July 23, 2026 | globenewswire.com

Rythm Stock Short Interest Report | NASDAQ:RYM | Benzinga

July 17, 2026 | benzinga.com

RYTHM (NASDAQ:RYM) Director Sells 2,250 Shares

June 19, 2026 | insidertrades.com

RYTHM Inc.

May 16, 2026 | marketwatch.com

Señorita Named Official THC Beverage Partner of Opry Entertainment Group Venues

May 14, 2026 | globenewswire.com

Rythm Inc Ordinary Shares RYM

May 13, 2026 | morningstar.comM

RYTHM Stock Price History

May 12, 2026 | investing.com

RYTHM's Q1 Earnings Rise Y/Y on Licensing Agreement Benefits

May 11, 2026 | zacks.com

Navy Pier Names RYTHM as Its Official THC Beverage Partner

May 8, 2026 | globenewswire.com

RYTHM, Inc. Reports First Quarter 2026 Results

May 5, 2026 | globenewswire.com

Turning nursery rhymes into lifelong learning moments

April 26, 2026 | msn.com

RYTHM Sets Fixed Licensing Fees to Support Listing

April 4, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DARE, INCR, CLNN, and RYM Company Descriptions

Clene NASDAQ:CLNN

$4.15 +0.29 (+7.51%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$4.12 -0.03 (-0.60%)

As of 04:00 AM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Dare Bioscience NASDAQ:DARE

$0.75 +0.02 (+3.07%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$0.76 +0.01 (+1.23%)

As of 04:23 AM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

InterCure NASDAQ:INCR

$5.31 0.00 (0.00%)

Closing price 09/17/2026 03:56 PM Eastern

Extended Trading

$5.28 -0.03 (-0.56%)

As of 09/17/2026 07:30 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

RYTHM NASDAQ:RYM

$22.49 +1.61 (+7.69%)

Closing price 09/17/2026 03:59 PM Eastern

Extended Trading

$22.40 -0.08 (-0.36%)

As of 09/17/2026 07:30 PM Eastern

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DARE, INCR, CLNN, and RYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DARE, INCR, CLNN, and RYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DARE, INCR, CLNN, and RYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DARE, INCR, CLNN, and RYM Company Descriptions

Clene NASDAQ:CLNN

Dare Bioscience NASDAQ:DARE

InterCure NASDAQ:INCR

RYTHM NASDAQ:RYM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DARE, INCR, CLNN, and RYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DARE, INCR, CLNN, and RYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DARE, INCR, CLNN, and RYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DARE, INCR, CLNN, and RYM Company Descriptions

Clene NASDAQ:CLNN

Dare Bioscience NASDAQ:DARE

InterCure NASDAQ:INCR

RYTHM NASDAQ:RYM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools